BiotechTube
Creasallis

Creasallis

London, United Kingdom· Est.
creasallis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Creasallis is an early-stage biotech addressing the significant limitation of antibody penetration in solid tumors, where typically only 0.001-7% of a dose reaches the target. Its core asset is the CreaTap platform, a universal modification technology that can be applied to various antibody formats (mAbs, ADCs, bispecifics) and even protein/peptide conjugates to improve tumor penetration. Operating as a platform company, Creasallis plans to both partner its technology for existing drugs and develop its own internal pipeline of enhanced therapeutics.

Oncology

Technology Platform

CreaTap (Tumour Antibody Penetration) - a patented, plug-and-play protein engineering technology designed to be a universal modification that enhances the penetration of antibody-based drugs and other protein/peptide therapeutics into solid tumors.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The technology addresses a fundamental, widely acknowledged bottleneck in solid tumor therapy, creating a large potential market across multiple antibody formats (mAbs, ADCs, bispecifics).
Its plug-and-play design could enable rapid partnerships and provide a path to generate near-term revenue and validation through collaborations with biopharma companies.

Risk Factors

The platform lacks publicly disclosed preclinical validation data.
Its universal applicability claim is ambitious and may not hold for all biologics, risking technical failure.
As a pre-revenue platform company, it is highly reliant on securing partnership deals or further funding to advance.

Competitive Landscape

Creasallis competes in the broad field of technologies aiming to improve drug delivery to tumors. Competitors include companies developing smaller antibody fragments (e.g., nanobodies), probody therapeutics, therapies targeting the tumor stroma, and novel nanoparticle or conjugate-based delivery systems. Its key differentiation is the claim of a single, universal modification for existing full-size antibodies.

More companies in United Kingdom →